Join partners Takeshi Nakao (Tokyo) and Vinita Kailasanath (Silicon Valley) for the latest episode of the Freshfields MedTech podcast. With a focus on Japan and the US, they discuss trends and innovations in MedTech, and potential risk and regulation that companies with MedTech products and services face.
Introduction (English translation): Hello everyone. My name is Takeshi, Managing Partner of Freshfields Tokyo Office. In today's podcast, we will discuss MedTech. MedTech is the word combining “medical” and “technology”, referring to using IOT and other technologies in healthcare. I will ask the speaker about this area, starting with the definition, which I am sure many of you have heard recently. Technology developments have led to many innovations in the field of healthcare, making it one of the growth areas and an area of high interest. Today I would like to bring you together with an expert in this field from the United States, Vinita Kailasanath. Vinita is the head of Freshfields' MedTech practice and has extensive experience in the field, particularly where both life sciences and technology are concerned. She has been involved in transactions that are strategically very important to our clients in the MedTech and digital health sectors. She provides advice in licensing transactions, research and development, and those kinds of areas. In fact, before becoming a lawyer, Vinita was doing research in the field of neuroendocrinology at the graduate level, which is a word I looked up in the dictionary. She also has experience providing marketing and sales support to pharmaceutical and biotech companies.
Outro (English translation): This time, we started with a high-level conversation with the theme of MedTech, explaining recent trends in regulations. Vinita is an expert in the field of MedTech, and we would like to send you another podcast when we hear about new developments as new trends emerge, etc.. Thank you for listening.
Reward(ing) Half Hour: Episode 2 Remuneration vs Compensation – the Transatlantic Pay Debate
No Worse Off #4: Richard Tett, 30 years in restructuring
Essential Antitrust #39: UK in-depth merger reviews: new process adopted by the CMA
No Worse Off #3: UK Restructuring Plans – Relevant Alternative, timetabling and jurisdiction
No Worse Off #2: After the battles, a coming of age for the UK restructuring plan?
Reward(ing) Half Hour: Being prepared for the (not so) unexpected: planning for executive exits
Tax Matters: Spring Budget 2024 – The Hunt for Blue October
No Worse Off #1: Overview of current restructuring trends
Essential Antitrust #38: What businesses can expect from China’s revised merger control regime
Impressions from the J.P. Morgan Healthcare Conference – A MedTech Perspective
Essential Antitrust #37: Antitrust in 2024: competition enforcement takes center stage
Legends of Tech #1: Turing with Vint and Whit: Boris Feldman in conversation with Vinton G. Cerf and Whitfield Diffie
Essential Antitrust Asia #9: updates with ABNR on antitrust in Indonesia
Managing Risk in Asia #8: Opportunities for Asian and US investors post-US Executive Order on outbound investments
Tax Matters: Trends in tax disputes – what should businesses be aware of?
Essential Antitrust #36: The UK’s Digital Markets, Competition and Consumers Bill – what you need to know
Essential Antitrust #35: Gender Inclusive Antitrust Toolkit: a new lens for policy and enforcement
Tax Matters: Autumn Statement 2023 – tax cuts in the NIC of time?
How secondaries have become primary to GPs and LPs
From chaos to control: making the case for legal project managers
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
Aligned Money Show
Gorse Culture PODcast : The H.R. Detective Agency!
HCI Leadership Revolution
The Ramsey Show
Planet Money